证券代码：301047 证券简称：义翘神州 公告编号：2025-035 北京义翘神州科技股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）2025 年半年度权益 分派方案已获 2025 年 9 月 11 日召开的 2025 年第一次临时股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过权益分派情况 1、公司于 2025 年 9 月 11 日召开 2025 年第一次临时股东大会，审议通过《关 于 2025 年半年度利润分配预案的议案》，公司 2025 年半年度利润分配方案为： 以公司总股本 121,636,742 股为基数，向全体股东每 10 股派发现金红利 40.00 元 （含税），拟合计派发现金红利总额为 486,546,968.00 元（含税），不送红股， 不以资本公积金转增股本。本次分红后的剩余未分配利润结转以后年度分配。 在权益分派预案披露日至实施权益分派股权登记日期间，若公司总股本发生变 动，将按照分配总额不变的原则相应调整，具体以实际派 ...

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

证券代码：301047 证券简称：义翘神州 公告编号：2025-034 北京义翘神州科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况。 一、会议召开情况 （一）会议召开时间 （1）现场会议时间：2025 年 9 月 11 日（星期四）14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 9 月 11 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为：2025 年 9 月 11 日 9:15-15:00 期间的任 意时间。 （二）会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 （三）会议召开地点：北京市北京经济技术开发区科创十街 18 号院 11 号楼 215 会议室。 （四）会议召集人：公司董事会。 （五）会议主持人：公司董事长谢良志博士。 （六）本次会议的召集 ...

北京市金杜律师事务所 关于北京义翘神州科技股份有限公司 2025 年第一次临时股东大会的法律意见书 致：北京义翘神州科技股份有限公司 北京市金杜律师事务所（以下简称本所）接受北京义翘神州科技股份有限公 司（以下简称公司）的委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管 理委员会（以下简称中国证监会）《上市公司股东会规则》（以下简称《股东会 规则》）等中华人民共和国境内（以下简称中国境内，为本法律意见书之目的， 不包括中国香港特别行政区、中国澳门特别行政区和中国台湾省）现行有效的法 律、行政法规、部门规章、规范性文件和现行有效的《北京义翘神州科技股份有 限公司章程》（以下简称《公司章程》）的规定，指派律师出席了公司于 2025 年 9 月 11 日召开的 2025 年第一次临时股东大会（以下简称本次股东大会）， 并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2024 年年度股东大会审议通过并于 2025 年 4 月 19 日刊登于深 圳证券交易所网站等中国 ...

Group 1 - The core point of the article is that Yiqiao Shenzhou announced the pledge of shares by its controlling shareholder, Lhasa Ailike Investment Consulting Co., Ltd. [2] - The number of pledged shares is 4,500,000, which represents 6.91% of the shares held by the controlling shareholder and 3.70% of the total share capital of the company [2]

Group 1 - The controlling shareholder of Yiqiao Shenzhou, Lhasa Ailike Investment Consulting Co., Ltd., pledged 4.5 million shares of the company on September 4, 2025, which accounts for 6.91% of its holdings and 3.70% of the company's total share capital [1] - The purpose of the pledged shares is for financing [1] - There are no significant asset restructuring or performance compensation obligations associated with the pledged shares [1]

证券代码：301047 证券简称：义翘神州 公告编号：2025-033 2、股东股份累计质押基本情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | 本次质押 | 本次质押 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | 持股数量 （股） | 持股 比例 | 前质押股 | 后质押股 | 持股份 | 总股本 | 已质押股份 限售和冻 | 占已 质押 | 未质押股 份限售和 | 占未质 | | | | | 份数量 （股） | 份数量 （股） | 比例 | 比例 | 结、标记数 | 股份 | 冻结数量 | 押股份 比例 | | | | | | | | | 量（股） | 比例 | （股） | | | 爱力克 | 65,140,056 | 53.55% | 15,000,000 | 19,500,000 | 29.94% | 16.03% | 0 | 0.00% | 0 | 0.00% | | 谢良志 | 2 ...

Group 1: Yiqiao Shenzhou - The company reported a more than 10% year-on-year growth in overseas conventional business revenue in the first half of the year, with the US being the primary market [1] - The performance of reagents was strong, while service revenue slightly declined due to large customer order impacts compared to the same period last year [1] - Future focus will be on enhancing reagent promotion, strengthening the sales team, and leveraging SCB's geographical advantages for business expansion [1] - The company will consider mergers and acquisitions that focus on technology complementarity, strategic regional layout, and upstream and downstream enterprises in the industry chain [1] - The sales volume of culture media business increased, but revenue and profit margins were affected by price competition [1] - The Taizhou subsidiary experienced rapid growth, while the Suzhou subsidiary faced longer expansion cycles due to certification requirements, with overall business showing stable growth [1] Group 2: Huaxiang Co., Ltd. - The company achieved a revenue of 1.98 billion yuan in the first half of the year, representing a year-on-year growth of 2.38%, and a net profit attributable to shareholders of 290 million yuan, up 25.66% year-on-year [2] - The profit growth outpaced revenue growth mainly due to an increase in the proportion of high-margin precision parts revenue to 80.8% and an improvement in gross margin to 23.3%, along with a decrease in expense ratio [2] - Financial expenses decreased primarily due to increased foreign exchange gains, with limited impact from the convertible bond delisting [2] - The company views the decline in white goods production as a temporary fluctuation and plans to offset pressure through increased automotive parts production, cost reduction via "short-process joint casting," and enhancing added value [2] - The company is expanding into the robotics sector, having initiated process validation for metal structural components of reducers, and plans to establish an industrial fund through external acquisitions [2] - Capital expenditure in the second half of the year will focus on "three park construction" to advance the expansion of automotive and industrial equipment industrial parks [2] - The mid-term dividend payout ratio reached 40.11%, with the annual dividend level to be announced later [2]

Group 1 - The core viewpoint of the article is that Yiqiao Shenzhou reported a more than 10% year-on-year growth in overseas regular business revenue for the first half of the year [1] - The United States remains the primary market for the company, with increased promotion of reagents overseas leading to better performance, although service revenue slightly declined due to large customer orders compared to the same period last year [1] - The company will continue to focus on the synergistic development of reagents and services, strengthen reagent promotion, enhance sales team building, and actively leverage SCB's geographical advantages to expand business and create new growth points [1]

Core Viewpoint - Yiqiao Shenzhou (301047) announced on September 4 that its current main product is liquid culture media, targeting the research sector, including research institutions and industrial clients' front-end research needs [1] Group 1: Company Overview - The company is experiencing an increase in sales volume of its culture media [1] - The company faces industry price competition, which is affecting the revenue scale and profit margins of related products [1]